<div id="readability-page-1"><div id="parent_top_div">Hyderabad-based biotechnology company BioVaram on Thursday said it has signed a MoU with Japan's Teijin Limited to collaborate on expanding usage of Regenerative Medicine products and Implantable medical devices in Japan and India. BioVaram, the University of Hyderabad incubated startup, is the brand name of the UR Advanced Therapeutics Pvt Ltd (URAT), a release said. The collaboration aims to expand the reach of Teijin Group's implantable medical devices and regenerative medicine products in India, while also introducing BioVaram's advanced product portfolio to the Japanese market, it said. &#34;Under the terms of the agreement, Teijin and BioVaram will explore the regulatory approval and commercialisation of SYNFOLIUM?, a cardiovascular repair patch by Teijin Medical Technologies Co, Ltd, in India,&#34; it said. The collaboration will open up opportunities for expanding use of Japan Tissue Engineering Co, Ltd's (part of the Teijin Group) regenerative medicine products in India. The agreement will also lead to the development and commercialisation in Japan of BioVaram technologies, including exosome-based diagnostics and therapeutics, Extracellular Matrix mimics, and bio-derived materials such as Type I atelocollagen. According to Takayuki Nakano, Mission Executive and General Manager, Regenerative Medicine &amp; Implantable Medical Device Division of Teijin Limited: &#34;The partnership with UR Advanced Therapeutics marks a highly significant step toward Teijin's global expansion in the fields of regenerative medicine and implantable medical devices.&#34; UR Advanced Therapeutics Founder and CEO Jaganmohan Reddy said the MoU with Teijin Limited reinforces BioVaram's vision to build transformative biotech innovations in India together with global partners. &#34;This partnership strengthens our capabilities in research, innovation, and scalable manufacturing of advanced tissue engineering products, while enabling Teijin to take BioVaram's products to global markets,&#34; he said.</div></div>

3401

總部位於海得拉巴的 BioVaram 與日本的帝人株式會社簽署了一份諒解備忘錄（MoU），旨在增強再生醫學產品和可植入醫療設備在印度和日本的應用。此次合作將重點關注帝人心血管修復補丁在印度的監管批准和商業化，並將促進 BioVaram 技術在日本的引入。該合作伙伴關係旨在加強先進組織工程產品的研究和製造能力，標誌着帝人在全球擴張努力中的重要一步

帝人公司與 BioVaram 簽署協議，致力於提供下一代醫療解決方案